Overactive Bladder Market New Entrants Are Targeting Specialty Physicians
Executive Summary
Recent entrants to the overactive bladder category are focusing on capturing market share through specialty physicians, Indevus Exec VP and Chief Sales & Marketing Officer John Tucker said
You may also be interested in...
FDA tells Pfizer to hold it
Pfizer receives an "approvable" letter from FDA for the overactive bladder treatment fesoterodine, which it acquired from Schwarz in April. Pfizer's market-leading urinary incontinence therapy Detrol LA (tolterodine) has been competing in an increasingly crowded market, and faces patent expiry in 2012 (1"The Pink Sheet" Aug. 15, 2005, p. 5)...
FDA tells Pfizer to hold it
Pfizer receives an "approvable" letter from FDA for the overactive bladder treatment fesoterodine, which it acquired from Schwarz in April. Pfizer's market-leading urinary incontinence therapy Detrol LA (tolterodine) has been competing in an increasingly crowded market, and faces patent expiry in 2012 (1"The Pink Sheet" Aug. 15, 2005, p. 5)...
Long-Acting Overactive Bladder Drugs Have Less Risk – Consumer Reports
Extended-release forms of overactive bladder drugs have better side effect profiles than their shorter-acting counterparts, according to Consumer Reports September 2006 "Best Buy Drugs.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: